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Abstract
Purpose/Objectives: For lung stereotactic body radiation therapy (SBRT), real-time
tumor tracking (RTT) allows for less radiation to normal lung compared to the internal
target volume (ITV) method of respiratory motion management. To quantify the
advantage of RTT, we examined the difference in radiation pneumonitis risk between
these two techniques using a normal tissue complication probability (NTCP) model.
Materials/Method: 20 lung SBRT treatment plans using RTT were replanned with
the ITV method using respiratory motion information from a 4D-CT image acquired
at the original simulation. Risk of symptomatic radiation pneumonitis was calculated
for both plans using a previously derived NTCP model. Features available before
treatment planning that identified significant increase in NTCP with ITV versus RTT
plans were identified.
Results: Prescription dose to the planning target volume (PTV) ranged from 22 to
60 Gy in 1–5 fractions. The median tumor diameter was 3.5 cm (range 2.1–5.5 cm)
with a median volume of 14.5 mL (range 3.6–59.9 mL). The median increase in PTV
volume from RTT to ITV plans was 17.1 mL (range 3.5–72.4 mL), and the median
increase in PTV/lung volume ratio was 0.46% (range 0.13–1.98%). Mean lung dose
and percentage dose–volumes were significantly higher in ITV plans at all levels tested.
The median NTCP was 5.1% for RTT plans and 8.9% for ITV plans, with a median dif-
ference of 1.9% (range 0.4–25.5%, pairwise P < 0.001). Increases in NTCP between
plans were best predicted by increases in PTV volume and PTV/lung volume ratio.
Conclusions: The use of RTT decreased the risk of radiation pneumonitis in all
plans. However, for most patients the risk reduction was minimal. Differences in
plan PTV volume and PTV/lung volume ratio may identify patients who would ben-
efit from RTT technique before completing treatment planning.
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1 | INTRODUCTION
“Stereotactic body radiation therapy” (SBRT) or “stereotactic ablative
body radiotherapy” (SABR) refers to highly spatially precise radiation
therapy with steep dose gradients delivered to an extracranial target,
typically completed in 1–5 fractions with higher doses per fraction
than conventional radiation therapy. For lung tumors, SBRT has
emerged as an effective treatment technique for early stage lung pri-
mary malignancies as well as lung oligometastases with outcomes
comparable to surgical resection.1,2
Lung SBRT has the particular challenge of tumor respiratory
motion. Some techniques for managing this include accounting for
motion within target volumes, temporarily reducing motion by breath
hold or abdominal compression, gating dose delivery by respiratory
phase, or tracking tumor motion during treatment using fluo-
roscopy.3 One of the most common techniques requiring no breath
control or imaging during treatment is expanding the target volume
to the entire range of tumor motion across the respiratory cycle,
known as the internal target volume (ITV). This is delineated using
CT scans obtained at maximum inhalation and exhalation, or a set of
scans acquired through the course of the respiratory cycle (4D-CT).
ITV technique has the disadvantage of including more normal lung
tissue in the target volume, exposing it to high radiation dose. It also
cannot account for unpredicted variations in tumor motion and res-
piratory pattern during treatment. Compensation may be achieved
with larger planning target volume (PTV) margins, but this further
increases the dose to normal lung tissue.4 To overcome these issues,
real-time tracking (RTT) techniques were developed such as the
CyberKnife robotic SBRT system with Synchrony motion manage-
ment (Accuray Inc., Sunnyvale CA, USA).5 With this system, tumor
motion is tracked during treatment while the patient breathes freely
without coaching. A correlation model is built between orthogonal
x-ray images acquired every 60–120 s and the positions of light
emitting diodes on the patient’s chest obtained by infrared camera
at 26 Hz. The model is continuously updated and used to move a
linear accelerator mounted on a robotic arm, anticipating target loca-
tion with high accuracy.6 The original Synchrony system required
invasive placement of gold fiducial markers near the tumor for accu-
rate targeting, associated with risks of pneumothorax, bleeding, and
additional treatment cost.7 The subsequently developed XSight Lung
Tracking system (Accuray Inc.) allows tracking based on imaging the
tumor itself, obviating the need for fiducial marker placement.8,9
However, this technique is limited to larger and denser tumors that
have adequate x-ray contrast with normal tissue.10
These motion management systems were primarily designed to
optimize target coverage. Less is known about their effects on normal
tissue doses, and complications have not been directly compared. The
most common adverse effects of lung SBRT are due to radiation of the
lung parenchyma, which incites a complex reaction leading to deple-
tion of alveolar pneumocytes, interstitial infiltration of immune cells,
and fibroblast proliferation.11 This manifests pathologically as a contin-
uum from subacute radiation pneumonitis to late pulmonary fibrosis,
which may be clinically symptomatic.12 The reported incidence for
symptomatic radiation pneumonitis requiring treatment after SBRT
ranges from 5% to 30%.13–22 This typically presents as a syndrome of
dyspnea, cough, and low-grade fever within 12 weeks of the comple-
tion of radiation therapy. Symptoms usually resolve with corticos-
teroids, although permanent pulmonary dysfunction can occur.12 The
lungs function as a classic radiobiological “parallel organ”23 and symp-
tomatic radiation pneumonitis is generally correlated with critical
dose–volumes rather than maximum dose to lung tissue.14,18,19,22 Nor-
mal tissue complication probability (NTCP) models based on mean lung
dose have been derived to predict risk of symptomatic radiation pneu-
monitis from lung SBRT.16,17,24
At our institution, it is standard for all lung SBRT patients to
undergo respiratory 4D-CT imaging at simulation regardless of the
intended motion management technique. This allows assessment of
target and organ motion and provides a backup method if fiducial- or
tumor-based tracking fails. In the current study, patients originally
treated using RTT were replanned using ITV volume expansion tech-
nique. Comparisons of planning parameters, lung dose–volumes, and
radiation pneumonitis NTCP from a previously derived model were
conducted. Classifications based on predosimetric characteristics were
performed to generate practical guidelines predicting which patients
could substantially benefit from real-time tracking, without needing to
perform time-consuming replanning and NTCP calculation.
2 | MATERIALS AND METHODS
A single institution database was used to retrospectively identify 20
SBRT treatment plans for primary or oligometastatic lung tumors. All
treatments were performed on the CyberKnife system with XSight
Lung Tracking RTT technique. The original treatment plans were
designed to deliver the prescription dose to a planning target volume
(PTVRTT), which was defined by an isotropic expansion from a gross
tumor volume (GTV) contoured on the simulation CT. The PTVRTT
margin expansion was determined by the treating physician at the
time of planning. Originally delivered treatment plans were used for
comparisons without modification.
For our study, each patient’s 8-phase respiratory 4D-CT images
obtained at the original simulation were restored. To delineate tumor
motion during a respiratory cycle, an internal target volume (ITV) was
contoured by superposition of GTVs contoured on each phase,
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following the movement of the original GTV as much as possible. This
was performed by the original treating physician at the time of initial
planning if available (2 plans), or by a single physician (C.C.) retrospec-
tively if not available. A new planning target volume (PTVITV) was cre-
ated using 5 9 598 mm (LR 9 AP 9 SI) expansion from the ITV, a
previously determined appropriate planning margin for this technique.4
New treatment plans targeting the PTVITV were generated using
the original prescription doses. Plans were designed using Accuray
Multiplan software v.5.2.0. Tissue heterogeneity correction was per-
formed by Monte Carlo algorithm with 1% uncertainty. Planning
goals were for prescription dose to cover ≥95% of PTVITV, and nor-
mal tissue doses to be as low as achievable while maintaining target
coverage. Doses to organs at risk (spinal cord, heart, esophagus, rib/
chest wall) had to meet TG-101 constraints25 except for rib/chest
wall, which was kept as low as possible while maintaining target cov-
erage. Prescription isodose line ≥60% of maximum dose was used if
able to maintain target coverage and normal tissue dose constraints.
The PTV volumes, prescription target coverage, prescription isodose
line, conformity index,26 total MU, estimated delivery time per frac-
tion, and doses to organs at risk were recorded. Figure 1 depicts
example RTT and ITV-based plans from a single patient.
The volume of bilateral lungs excluding GTV was defined for
each plan. Dose–volume histograms for the bilateral lung volumes
were extracted with bin size 0.1 Gy. Doses were converted to the
linear-quadratic equivalent dose in 2 Gy fractions (EQD2) using a/
b = 3.27 After conversion, the mean dose to bilateral lungs was
recorded, as well as the following dose volume percentages based
on previous publications identifying correlations to radiation pneu-
monitis risk: V2.5 Gy, V5 Gy, V10 Gy, V13 Gy, V20 Gy, V30 Gy,
V40 Gy, and V50 Gy.16,17,24,28 The normal tissue complication prob-
ability (NTCP) for symptomatic radiation pneumonitis requiring treat-
ment (grade ≥2 by NCI-CTCAE v.4) was calculated from a previously
published model using the Lyman-Kutcher-Burman formula based on
bilateral lung mean dose using TD50 = 20.8 Gy, m = 0.45.17 For
patients with multiple tumors, each tumor was planned separately
and doses were considered independently.
Statistical analysis was performed using non-parametric tests in R
v.3.3.2 (R Foundation for Statistical Computing).29 To compare treat-
ment plan dosimetry, pairwise Wilcoxon rank-sum tests were used. To
correlate differences in NTCP to tumor and treatment features, Spear-
man’s rank correlation coefficient was used. All statistical tests were
two-sided with a significance threshold of P ≤ 0.05. To create a practi-
cal guideline to identify patients before dosimetric calculation who
would have a meaningfully increased risk of radiation pneumonitis with
ITV versus RTT planning, an increase in NTCP of >5% was designated
as “clinically significant”. This threshold was chosen by agreement that
this was the highest increase in NTCP that would be accepted for plans
to be considered clinically equivalent. Receiver operating characteristic
(ROC) analysis was used to compare the ability of features available
before dosimetric calculation (“pre-dosimetric variables”) to predict
which patients would have these increases in NTCP.
3 | RESULTS
3.A | Plan characteristics and NTCP
We identified 20 RTT plans delivered to 18 patients (two patients
had two tumors treated by separate plans). Twelve patients were
male and the median age was 73 yr (range 26–95 yr). Fourteen
treatments were for lung primary tumors and six for metastatic
tumors. Table 1 details the tumor locations, size, and extent of
motion, as well as prescription doses (delivered and EQD2) and
PTVRTT margins. Two tumors were considered central by RTOG
0813 criteria (within 2 cm of the proximal bronchial tree).30
Comparisons of RTT and ITV plans are in Table 2. As expected,
the PTV volume was significantly larger in ITV than RTT plans (me-
dian difference 17.1 mL, range 3.5–72.4 mL, P < 0.001) and the ratio
of the PTV volume to total bilateral lung volume (PTV/lung) was also
larger (median difference 0.46%, range 0.13–1.98%, P < 0.001).
There were no significant differences in PTV prescription coverage,
prescription isodose percentages, or conformity indices. There were
also no significant differences in maximum doses to the organs at
risk other than the lungs (Table S1).
The mean lung dose was significantly higher for ITV plans, with a
median increase in 1.95 Gy (range 0.22–7.37 Gy, P < 0.001). Lung
dose–volume percentages were also significantly higher at every level
tested, with greater increases at the lower dose–volumes (Table 2,
F I G . 1 . Example plan comparison with coronal slices of treatment
planning CT for RTT plan (a) and ITV plan (b). GTV is shaded blue,
ITV is shaded purple, and PTVs are shaded red. From RTT to ITV
based-plan, PTV volume increased 36.4 mL, PTV/lung volume ratio
increased 0.69%, and NTCP increased 4.1%.
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Fig. 2). The median NTCP for RTT plans was 5.1% (range 2.1–17.2%),
while the median NTCP for ITV plans was 8.9% (range 3.5–41.1%). The
median RTT-to-ITV increase in NTCP was 1.9% (range 0.4–25.5%,
P < 0.001). The increase in NTCP between plans was significantly cor-
related to the NTCP value for the ITV plan (q = 0.63, P = 0.004), but
not to the NTCP value for the RTT plan (q = 0.32, P = 0.18).
3.B | Pre-dosimetric variable correlations to
increase in NTCP
Correlations between predosimetric variables and the increase in
NTCP between RTT and ITV plans are in Table 3. Increase in NTCP
was most strongly correlated with the increase in PTV/lung volume
ratio from RTT to ITV plan (q = 0.79, P < 0.001), and the increase in
PTV volume from RTT to ITV plan (q = 0.74, P < 0.001). High corre-
lations were also seen for PTVITV/lung volume ratio (q = 0.66,
P = 0.002), and GTV greatest axial diameter (q = 0.63, P = 0.003).
Statistically significant but weaker correlations were also seen for
other measures related to tumor size and motion such as GTV vol-
ume, ITV volume, ITV  GTV volume difference, and PTV volumes.
Prescription dose, lung volume alone, and measures of tumor linear
motion alone were not statistically significantly correlated with
increase in NTCP between RTT and ITV plans.
3.C | Sensitivity analysis
The size of the PTVRTT margin used in the original plans was corre-
lated with tumor size and was potentially a confounder. A sensitivity
analysis was performed limiting the comparisons to the 14 plans
with an original 5 mm PTVRTT margin, which tended to be used for
smaller tumors. The median GTV was 12.9 mL for tumors with
5 mm PTVRTT margin versus for 14.5 mL for all tumors (Tables
S2–S4). The increase in NTCP from RTT to ITV plans remained sig-
nificant, with a median increase in 1.2% (P < 0.001). The increase in
PTV volume and PTV/lung volume ratio from RTT to ITV plans also
remained significantly correlated with increase in NTCP (increase in
PTV volume: q = 0.57, P = 0.03; increase in PTV/lung volume ratio:
q = 0.55, P = 0.04).
3.D | ROC analysis
For the purposes of identifying tumors that would derive a clinically
meaningful reduction in radiation pneumonitis risk with an RTT plan
versus an ITV-based plan, a >5% difference in NTCP was designated
as “clinically significant”. Of the 20 plans, five had clinically signifi-
cant increases in NTCP using ITV versus RTT. ROC analysis was
used to identify predictive thresholds in the four predosimetric vari-
ables that were most highly correlated with change in NTCP from
RTT to ITV plans (difference in PTV/lung volume ratio, difference in
PTV volume, PTVITV/lung volume ratio, and GTV greatest axial diam-
eter). ROC curves are depicted in Fig. 3.
Increase in PTV/lung volume ratio from RTT to ITV plan was
the most accurate predictor of clinically significant increase in
NTCP, with ROC area under curve (AUC) of 100%. The most sensi-
tive threshold was an increase in PTV/lung volume ratio of 0.973%
[sensitivity 100%, specificity 100%; Fig. 4(a)]. The next best predic-
tor was the increase in PTV volume from RTT to ITV plan, with
AUC 95%. The most sensitive threshold was an increase in PTV
volume 24.0 mL [sensitivity 100%, specificity 87% (2 false posi-
tives); Fig. 4(b)]. The PTVITV/lung volume ratio also had AUC 95%,
with the most sensitive threshold being 2.08% [sensitivity 100%,
specificity 87% (2 false positives); Fig. 4(c)]. The least accurate pre-
dictor of these four variables was GTV greatest axial diameter, with
AUC 85%. The most sensitive threshold was diameter 3.4 cm [sen-
sitivity 100%, specificity 60% (6 false positives); Fig. 4(d)]. Using a
TAB L E 1 Lung tumor SBRT plan characteristics.
Plan characteristics (n = 20)
Number (percentage) or
median (range)
Lobe
RUL 9 (45%)
LLL 5 (25%)
LUL 2 (10%)
RML 2 (10%)
RLL 1 (5%)
Lingula 1 (5%)
Location
Peripheral 18 (90%)
Central 2 (10%)
Total bilateral lung volume 3421 mL (2298 to 6228 mL)
GTV greatest axial diameter 3.5 cm (2.1 to 5.5 cm)
GTV volume 14.5 mL (3.6 to 59.9 mL)
ITV volume 23.3 mL (4.6 to 77.7 mL)
ITV subtract GTV volume 5.5 mL (1.0 to 22.3 mL)
Tumor motion
Superior–inferior 4.5 mm (0 to 20 mm)
Anterior–posterior 3 mm (0 to 9 mm)
Left–right 2 mm (0 to 8 mm)
Prescription dose and fractions
60 Gy in 5 fractions 2 (10%)
54 Gy in 3 fractions 3 (15%)
50 Gy in 5 fractions 7 (35%)
48 Gy in 4 fractions 2 (10%)
42.5 Gy in 5 fractions 1 (5%)
37.5 Gy in 3 fractions 1 (5%)
25 Gy in 1 fraction 2 (10%)
24 Gy in 1 fraction 1 (5%)
22 Gy in 1 fraction 1 (5%)
Prescription EQD2 (a/b = 3) 130 Gy (97.75 to 226.8 Gy)
Isotropic PTVRTT margin
5.0 mm 14 (70%)
2.5 mm 4 (20%)
2.0 mm 2 (10%)
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threshold of 4.0 cm improved the specificity [sensitivity 80% (1
false negative), specificity 80% (3 false positives); Fig. 4(d)]. How-
ever, AUC estimates were not statistically significantly different
from each other.
4 | DISCUSSION
In this series of 20 lung SBRT plans using a real-time tracking (RTT)
technique for respiratory motion management, we found that
TAB L E 2 Planning and dosimetric characteristics of ITV and RTT plans.
Target
ITV RTT Pairwise difference (ITV  RTT)
Median Range Median Range Median Range P
PTV volume (mL) 60.0 21.3–160.6 33.1 6.6–88.2 17.1 3.5–72.4 <0.001
PTV/lung (%) 1.53 0.58–4.40 1.00 0.16–2.42 0.46 0.13–1.98 <0.001
PTV coverage (%) 95.5 95.0–97.0 95.6 95.0–96.7 0 1.4 to 1.1 0.76
Rx IDL (%) 62.0 60.0–73.0 63.0 51.0–74.0 0.5 13.0 to 10.0 0.92
Conformity index 1.08 1.01–1.19 1.10 0.98–1.36 0.02 0.32 to 0.10 0.19
Total MU 48,930 26,024–77,100 36,132 14,018–50,722 15,690 8236 to 36,977 <0.001
Minutes per fraction 45.5 36–73 33 24–57 12.5 2–40 <0.001
Bilateral lung
Mean (Gy) 8.20 3.84–18.7 5.49 1.72–11.95 1.95 0.22–7.37 <0.001
V2.5 Gy (%) 34.2 14.6–57.5 27.1 10.1–40.7 8.9 0.2–19.7 <0.001
V5 Gy (%) 22.7 8.3–41.5 18.3 5.5–32.9 3.4 1.0 to 12.6 <0.001
V10 Gy (%) 13.6 5.3–29.0 11.0 3.5–21.3 2.0 2.6 to 7.7 0.001
V13 Gy (%) 10.9 4.4–24.4 8.9 2.7–18.4 1.6 2.6 to 6.3 0.004
V20 Gy (%) 7.7 3.3–16.1 6.2 1.7–13.0 1.0 1.5 to 4.8 0.003
V30 Gy (%) 5.4 2.4–11.8 4.4 1.1–9.7 0.9 1.0 to 3.4 0.002
V40 Gy (%) 4.2 1.9–9.5 3.4 0.8–7.8 0.8 0.7 to 3.0 0.001
V50 Gy (%) 3.8 1.6–8.0 2.8 0.6–6.5 0.8 0.6 to 2.6 0.001
NTCP (%) 8.9 3.5–41.1 5.1 2.1–17.2 1.9 0.4–25.5 <0.001
0
20
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F I G . 2 . Boxplots of lung dose–volume
percentages by plan type.
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changing to an internal target volume (ITV) technique would have
increased the radiation pneumonitis risk for every plan, up to 25%.
However, for half of the patients this increase in normal tissue com-
plication probability (NTCP) would have been minimal (<2%), and
only 25% of patients would have experienced a “clinically significant”
increase in >5%. The most predictive factors of a NTCP increase
were differences between plans in PTV volume and PTV/lung vol-
ume ratio, however the PTVITV/lung volume and the GTV greatest
axial diameter were also strong predictors. While different PTVRTT
expansion margins were used for some patients, a sensitivity analysis
showed that differences in PTV volume and PTV/lung volume ratio
remained significant predictors of NTCP in a uniform margin sub-
group. We identified thresholds in these variables to predict which
patients would have no clinically significant increase in NCTP with
an ITV versus an RTT based plan. These patients could be identified
even before completing treatment planning, saving time needed to
create multiple plans for comparison. There were otherwise no sig-
nificant differences in RTT and ITV plan quality as assessed by target
prescription dose coverage, conformity index, prescription isodose
level, or doses to other organs at risk.
Reviewing which predosimetric variables predicted greater NTCP
increase in this study (Table 3), it makes some intuitive sense that
features which incorporated both target volume and motion, as well
as their relation to normal lung volume, would have the greatest pre-
dictive value. Measurements of tumor volume alone (GTV volume)
or motion alone (ITV  GTV volume difference, superior-inferior
motion) were less predictive, although GTV greatest axial diameter
was strongly correlated. This may be due to the fact that in this
dataset, smaller tumors were more often planned with a small
PTVRTT margin. None of the features except those based on differ-
ences between plans (increase in PTV volume, increase in PTV/lung
ratio) remained significant in the uniform margin sensitivity analysis.
Prescription dose was not a significant predictor within the range of
doses delivered in this study, possibly because most dose/fractiona-
tion schemes are designed to have comparable toxicities. Metrics
related to the PTVITV had greater correlation with the change in
NTCP than those related to PTVRTT. This is likely due to the sig-
moidal nature of the NTCP curve, as the plan with the higher NTCP
closer to the steepest portion of the curve (50%) would determine
more of the change. This is also demonstrated by the NTCP differ-
ence being more correlated with the NTCP from the ITV plan than
the RTT plan. While the median difference in NTCP was only 2%
and three-quarters of patients had <5% difference in NTCP, there
was one outlier patient with an estimated increase in NTCP 25.5%
(NTCP 41% with ITV-based plan). This female patient had a left
lower lobe tumor that received 54 Gy in 3 fractions using a 2.5 mm
PTVRTT margin. Her total lung volume was 3335 mL, near the med-
ian. She was not an outlier on tumor size or motion, although she
was near the top of the range for both (GTV 42.9 mL, second high-
est; 18 mm SI motion, second highest). This example demonstrates
again how both tumor size and motion contribute to the estimated
NTCP benefit from RTT planning.
Two similar studies on the effect of respiratory motion manage-
ment on radiation pneumonitis risk were identified in the literature.
Depuydt et al. compared ITV planning to RTT technique on a gim-
baled SBRT system.31 They found a statistically significant mean
improvement in NTCP of 0.69% with the RTT technique. This is
smaller than the current study, however the tumor volumes were
also much smaller: median 4.15 mL in that study versus 14.5 mL in
the current study. A different NTCP model was also used.32 Kim
et al. compared ITV-based plans to respiratory gated plans in 150
patients.33 Gated plans reduced the mean lung dose less than
0.5 Gy (EQD2) on average, and reduced the mean lung V20 Gy by
TAB L E 3 Spearman’s rank correlation coefficient for predosimetric
variables and increase in NTCP from RTT to ITV plan.
Predosimetric variable q P
Prescription dose EQD2 0.25 0.29
Total lung volume 0.23 0.32
GTV greatest axial diameter 0.63 0.003
GTV volume 0.56 0.01
ITV volume 0.56 0.01
ITV  GTV volume difference 0.52 0.02
PTVRTT volume 0.46 0.04
PTVITV volume 0.59 0.008
Increase in PTV volume 0.74 <0.001
PTVRTT/lung volume ratio 0.43 0.06
PTVITV/lung volume ratio 0.66 0.002
Increase in PTV/lung volume ratio 0.79 <0.001
Superior–inferior motion 0.20 0.39
Anterior–posterior motion 0.02 0.92
Left–right motion 0.10 0.69
F I G . 3 . ROC curves for analyzed predosimetric variables for
predicting increase in NTCP > 5%.
CHAPMAN ET AL. | 53
<0.5%. NTCP was not calculated, but the expected risk reduction
would be small. However, the mean lung doses in that study were
also low regardless of planning technique, approximately 3.0–3.5 Gy
versus a median of 5.5 Gy for RTT plans and 8.2 Gy for ITV plans in
the current study.
These comparisons highlight some of the limitations of this work.
First, the influence of tumor size on radiation pneumonitis risk
makes the results dependent on the studied population. We limited
our study to patients with tumors visible on orthogonal X rays using
XSight Lung Tracking technique, thus having on average larger
tumors that would benefit more from RTT.10 Second, the estimations
of radiation pneumonitis risk are dependent on the NTCP model
used. We selected the model used in this study from one of the
largest SBRT-specific studies with prospectively collected toxicity
data, which evaluated a variety of different dose-fractionation
schemes, a/b ratios, and NTCP models.17 However, to our knowl-
edge the selected model has not been validated in a second sample
and may have dependencies particular to the original group. In that
study, models with a linear component for high dose per fraction
radiation fell within the 95% confidence interval of the standard lin-
ear-quadratic models.17 However, uncertainty remains regarding the
applicability of the linear-quadratic model to highly hypofractionated
radiation therapy.34 Studies requiring retrospective replanning are
also subject to bias. While two plans had ITVs available from the
time of initial planning, the remainder were contoured retrospec-
tively and may be different than what the original treating physician
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would have contoured. The RTT and ITV plans appeared to be simi-
lar quality as measured by target coverage, conformity, and hetero-
geneity (Table 2), but it remains possible that there were some
differences in planning technique that influenced the results. Thus,
while we propose some predosimetric variables that in principle
could predict differences in NTCP between RTT and ITV plans, these
require further validation in a larger prospective dataset before clini-
cal use.
There were some choices made in the methodology of this study
that require further explanation. First, we decided not to replan the
original RTT plans with a uniform PTVRTT margin for all patients. For
the original plans, the treating physicians made individualized deci-
sions on PTV margin based on tumor motion, location, and other
features. Although the PTVRTT margins are different, they are consis-
tent in that they were all approved by the initial treating physicians
as clinically acceptable plans. For the ITV-based plans, one may
expect to have different PTV margins than RTT due to the different
motion management technique alone. Rather than adjust the PTVITV
margins per patient based on the original PTVRTT margin (the ratio-
nale for which may no longer apply in the ITV setting), we chose a
consistent PTVITV margin based on previously published measures of
intrafraction tumor motion.4 We then performed a sensitivity analy-
sis limited to patients with 5 mm PTVRTT margins, which did not
substantially alter our findings. We also made a choice to designate
an NTCP difference of >5% as a “clinically significant” difference
between plans. While somewhat arbitrary, identifying thresholds like
this can be useful for clinical decision-making. The authors agreed
that this is the highest difference in NTCP between plans that would
be acceptable to consider them clinically equivalent. In the relevant
range of NTCP the 1 SD confidence interval of the model used is
approximately 2.5%, therefore any predicted changes in NTCP
below 5% may also be less reliable.17 The purpose of identifying pre-
dosimetric variables that predict difference in NTCP was to help clin-
icians to easily identify which patients would substantially benefit
from RTT technique. While the most accurate approach would be to
simply create both RTT and ITV-based plans and compare dosimetry,
in our experience it can take several hours to create a single lung
SBRT plan. The variables proposed can be obtained with contouring
only. Although not addressed in this study, patients who would not
benefit from RTT technique may be also good candidates for an ITV-
based plan on a different system, thereby saving use of CyberKnife
as a limited resource.
There are several factors besides pneumonitis risk that must be
considered when choosing a motion management technique. If the
target is close to organs at risk such as the heart or esophagus,
greater motion management may be needed just to achieve these
planning constraints. In this study there were no statistically signifi-
cant differences in maximum doses to other organs by treatment
technique across the group (Table S1). All planning constraints were
met, and some ITV-based plans had even lower maximum organ
doses than the matching RTT plans, likely due to differences in plan-
ning techniques and optimization goals. The lack of significant differ-
ences across the group is also due to tumors being in various
locations throughout the lungs. However, as can be seen from the
table, individual patients did have differences in organ maximum
doses that may approach clinical significance. Target accuracy may
also be affected by motion management technique. In the Cyber-
Knife system, alignment is performed on the spinal column when
using ITV-based planning and the target itself is not localized prior
to or during treatment. Tumors further away from the spine thus
have greater targeting errors, and the application of this technique
should be carefully evaluated on a case-by-case basis. A preliminary
study suggests that using spine alignment as surrogate for lung
tumor localization may result in local misses and ultimately decrease
tumor control.35 ITV-based planning also assumes that 4D-CT ade-
quately captures all tumor motion, although motion can vary widely
within and between fractions.36 Motion management technique also
affects treatment delivery time. We found a median decrease in
12.5 min per fraction for RTT plans due to smaller target volume
and lower MU count (Table 2). However, this does not take into
account RTT pretreatment imaging and correlation model building
which increase the total “on table” time, particularly for patients with
irregular breathing patterns. It is reasonable to assume that the total
resource utilization time may be actually higher for RTT than ITV-
based plans. Furthermore, ITV-based plans can be delivered using
volumetric arc planning, which is much faster than CyberKnife and
allows 3D target localization. Treatment indications and comorbid
conditions also must be considered. Lung SBRT for oligometastatic
disease may be given for prophylaxis or palliation of symptoms, and
treatment-related toxicities may be considered less acceptable from
a risk-benefit perspective. Oligometastatic patients are also more
likely to receive radiation to multiple lung tumors increasing total
lung dose, and to receive systemic agents that may also increase
pneumonitis risk. Two patients in this study had multiple tumors
treated using SBRT, however, this was not taken into account when
calculating radiation pneumonitis risk and may be expected to raise
it substantially.
Thus, while also considering these other factors, the capability to
identify patients who would benefit from RTT is valuable. If they
would benefit, clinicians may recommend attempts at XSight lung
tracking, fiducial implantation, or other strategies for motion man-
agement. If they would not benefit, clinicians could opt for ITV-
based treatment either on the Cyberknife or a conventional linear
accelerator. In the present study we both quantify the range of
expected differences in radiation pneumonitis risk between motion
management techniques and propose some variables that may pre-
dict this benefit without requiring dosimetric calculation.
5 | CONCLUSION
The use of a real-time tumor tracking technique decreased radiation
pneumonitis risk for all patients, although for most this absolute risk
reduction was small (<5%). Difference between plans in the ratio of
the target volume to total lung volume was the best predosimetric
predictor of whether patients would derive a clinically significant
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benefit from real-time tumor tracking technique. Prospective data
collection in a larger sample would validate the use of this NTCP
model and the estimated effect of different respiratory motion man-
agement techniques.
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SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information section at the end of the article.
Table S1. Maximum doses to non-lung OARs for ITV and RTT
plans.
Table S2. Sensitivity analysis: characteristics of 14 plans with
PTVXLT margin 5.0 mm for sensitivity analysis.
Table S3. Sensitivity analysis: dosimetric comparison of 14 plans
with PTVRTT margin 5.0 mm.
Table S4. Sensitivity analysis: correlation of predosimetric vari-
ables to change in NTCP risk for 14 plans with PTVRTT margin
5.0 mm.
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